[Part VI. Antiparasitic treatment for Chagas disease].
As expert consensus has been arisen about universal antiparasitic treatment for all patients infected with Trypanosoma cruzi, most important drugs licensed for Chagas disease treatment are reviewed: nifurtimox and benznidazol, their mechanisms of action, doses, treatment schedules, adverse effects and contraindications. Two other drugs used for Chagas disease treatment, for which a Chilean experience may be exhibited, are allopurinol and itraconazole. Indications for treatment of Chagas disease in immunocompetent patients and immunocompromised hosts are detailed. This chapter refers besides to the evaluation and monitoring of antiparasitic therapy in immunocompromised patients, the availability of drugs and includes various forms facsimiles suggested to perform clinical and laboratory follow up of patients that undergo treatment, indicating the prescribed drug, adverse effects and time of follow up.
B
Werner Apt
WA
Comité de Parasitología, Departamento de Enfermedades Emergentes y Re-emergentes, Ministerio de Salud, Chile.
G
Ingrid Heitmann
IH
L
M Isabel Jercic
MI
M
Leonor Jofré
LJ
V
Patricia Muñoz C Del
PM
H
Isabel Noemí
IN
V
Ana M San Martín
AM
P
Jorge Sapunar
JS
H
Marisa Torres
MT
A
Inés Zulantay
IZ
D000493:Allopurinol / Q000627:therapeutic use; D000818:Animals; D014355:Chagas Disease / Q000145:classification / Q000188:drug therapy*; D005500:Follow-Up Studies; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D009547:Nifurtimox / Q000627:therapeutic use; D009593:Nitroimidazoles / Q000627:therapeutic use; D014344:Trypanocidal Agents / Q000627:therapeutic use*; D014349:Trypanosoma cruzi / Q000187:drug effects
D007166:Immunosuppressive Agents; D009593:Nitroimidazoles; D014344:Trypanocidal Agents; D000493:Allopurinol; D009547:Nifurtimox; C009999:benzonidazole